RaQualia Pharma Inc.
4579.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | ¥3,107,575 | ¥1,901,202 | ¥2,918,038 | ¥2,776,233 |
| % Growth | 63.5% | -34.8% | 5.1% | – |
| Cost of Goods Sold | ¥625,759 | ¥245,053 | ¥231,586 | ¥320,674 |
| Gross Profit | ¥2,481,816 | ¥1,656,149 | ¥2,686,452 | ¥2,455,559 |
| % Margin | 79.9% | 87.1% | 92.1% | 88.4% |
| R&D Expenses | ¥1,703,962 | ¥1,372,000 | ¥1,248,678 | ¥1,127,397 |
| G&A Expenses | ¥991,236 | ¥620,954 | ¥571,538 | ¥620,301 |
| SG&A Expenses | ¥991,236 | ¥620,954 | ¥571,538 | ¥620,301 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥1 | ¥561 | ¥0 | ¥0 |
| Operating Expenses | ¥2,695,199 | ¥1,993,515 | ¥1,820,216 | ¥1,747,698 |
| Operating Income | -¥213,383 | -¥337,365 | ¥866,235 | ¥707,860 |
| % Margin | -6.9% | -17.7% | 29.7% | 25.5% |
| Other Income/Exp. Net | -¥144,349 | ¥43,316 | -¥15,224 | ¥172,719 |
| Pre-Tax Income | -¥357,732 | -¥294,049 | ¥851,011 | ¥880,579 |
| Tax Expense | ¥137,298 | ¥29,612 | ¥127,620 | ¥124,790 |
| Net Income | -¥495,031 | -¥323,662 | ¥723,390 | ¥755,788 |
| % Margin | -15.9% | -17% | 24.8% | 27.2% |
| EPS | -22.87 | -14.98 | 34.5 | 36.07 |
| % Growth | -52.7% | -143.4% | -4.4% | – |
| EPS Diluted | -22.87 | -14.98 | 34.47 | 36.04 |
| Weighted Avg Shares Out | 21,645 | 21,606 | 20,969 | 20,953 |
| Weighted Avg Shares Out Dil | 21,645 | 21,606 | 20,983 | 20,972 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥8,273 | ¥9,698 | ¥13,656 | ¥22,849 |
| Interest Expense | ¥184,114 | ¥6,681 | ¥5,995 | ¥1,454 |
| Depreciation & Amortization | ¥401,653 | ¥175,564 | ¥147,731 | ¥141,555 |
| EBITDA | ¥188,271 | -¥111,801 | ¥1,004,736 | ¥1,023,587 |
| % Margin | 6.1% | -5.9% | 34.4% | 36.9% |